Rhumbline Advisers Kura Oncology, Inc. Transaction History

Rhumbline Advisers

  • $104 Billion
  • Q1 2025

A detailed history of Rhumbline Advisers transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 105,206 shares of KURA stock, worth $741,702. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,206
Previous 99,991 5.22%
Holding current value
$741,702
Previous $870,000 14.83%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 08, 2025
BUY
$7.05 - $9.05 $36,765 - $47,195
5,215 Added 5.22%
105,206 $741,000
Q4 2024

Jan 30, 2025
BUY
$8.51 - $19.21 $16,364 - $36,940
1,923 Added 1.96%
99,991 $870,000
Q3 2024

Nov 12, 2024
SELL
$18.57 - $23.23 $113,425 - $141,888
-6,108 Reduced 5.86%
98,068 $1.92 Million
Q2 2024

Aug 01, 2024
SELL
$17.53 - $22.98 $165,342 - $216,747
-9,432 Reduced 8.3%
104,176 $2.14 Million
Q1 2024

May 09, 2024
BUY
$13.42 - $23.53 $20,733 - $36,353
1,545 Added 1.38%
113,608 $2.42 Million
Q4 2023

Feb 08, 2024
BUY
$7.58 - $14.38 $8,997 - $17,069
1,187 Added 1.07%
112,063 $1.61 Million
Q3 2023

Nov 09, 2023
BUY
$8.44 - $11.86 $44,394 - $62,383
5,260 Added 4.98%
110,876 $1.01 Million
Q2 2023

Aug 08, 2023
BUY
$9.62 - $13.99 $15,517 - $22,565
1,613 Added 1.55%
105,616 $1.12 Million
Q1 2023

May 11, 2023
BUY
$10.71 - $14.6 $35,343 - $48,180
3,300 Added 3.28%
104,003 $1.27 Million
Q4 2022

Feb 14, 2023
BUY
$11.23 - $16.9 $26,716 - $40,205
2,379 Added 2.42%
100,703 $1.25 Million
Q3 2022

Nov 10, 2022
BUY
$12.01 - $19.45 $80,863 - $130,956
6,733 Added 7.35%
98,324 $1.34 Million
Q2 2022

Aug 11, 2022
BUY
$10.71 - $18.33 $86,815 - $148,582
8,106 Added 9.71%
91,591 $1.68 Million
Q1 2022

May 12, 2022
SELL
$11.78 - $16.98 $84,003 - $121,084
-7,131 Reduced 7.87%
83,485 $1.34 Million
Q4 2021

Feb 10, 2022
SELL
$12.22 - $19.57 $13,735 - $21,996
-1,124 Reduced 1.23%
90,616 $1.27 Million
Q3 2021

Nov 12, 2021
BUY
$15.42 - $21.72 $44,718 - $62,988
2,900 Added 3.26%
91,740 $1.72 Million
Q2 2021

Aug 05, 2021
BUY
$20.85 - $29.88 $443,020 - $634,890
21,248 Added 31.44%
88,840 $1.85 Million
Q1 2021

May 06, 2021
SELL
$24.75 - $39.14 $61,825 - $97,771
-2,498 Reduced 3.56%
67,592 $1.91 Million
Q4 2020

Feb 10, 2021
BUY
$29.0 - $41.62 $205,639 - $295,127
7,091 Added 11.26%
70,090 $2.29 Million
Q3 2020

Nov 12, 2020
SELL
$16.3 - $30.64 $136,268 - $256,150
-8,360 Reduced 11.72%
62,999 $1.93 Million
Q2 2020

Aug 13, 2020
BUY
$7.95 - $18.81 $229,580 - $543,195
28,878 Added 67.98%
71,359 $1.16 Million
Q1 2020

May 06, 2020
BUY
$6.45 - $14.04 $1,812 - $3,945
281 Added 0.67%
42,481 $423,000
Q4 2019

Feb 05, 2020
BUY
$12.97 - $15.94 $22,554 - $27,719
1,739 Added 4.3%
42,200 $580,000
Q3 2019

Oct 23, 2019
BUY
$14.75 - $20.87 $39,072 - $55,284
2,649 Added 7.01%
40,461 $614,000
Q2 2019

Aug 14, 2019
BUY
$14.71 - $19.79 $22,109 - $29,744
1,503 Added 4.14%
37,812 $745,000
Q1 2019

May 01, 2019
SELL
$13.73 - $16.87 $11,107 - $13,647
-809 Reduced 2.18%
36,309 $602,000
Q4 2018

Jan 31, 2019
BUY
$10.6 - $17.49 $146,078 - $241,029
13,781 Added 59.05%
37,118 $521,000
Q3 2018

Nov 07, 2018
SELL
$16.65 - $21.85 $5,161 - $6,773
-310 Reduced 1.31%
23,337 $408,000
Q2 2018

Aug 06, 2018
BUY
$14.8 - $18.8 $82,169 - $104,377
5,552 Added 30.68%
23,647 $430,000
Q1 2018

May 02, 2018
BUY
$14.5 - $23.4 $60,320 - $97,344
4,160 Added 29.85%
18,095 $339,000
Q4 2017

Feb 09, 2018
SELL
$13.5 - $16.65 $12,285 - $15,151
-910 Reduced 6.13%
13,935 $213,000
Q3 2017

Nov 06, 2017
BUY
$6.05 - $14.95 $89,812 - $221,932
14,845
14,845 $222,000

Others Institutions Holding KURA

# of Institutions
193
Shares Held
77.3M
Call Options Held
103K
Put Options Held
106K
View Full List

About Kura Oncology, Inc.

KURA Quotes by TradingView
  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $472M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email